A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains a principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect.
wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by:
etc.
studies indicated that the present rhodium-catalyzed [2+2+2] cycloaddition proceeds through the rhodacyclopentadiene intermediate generated by oxidative coupling of a diyne with rhodium. On the other hand, in the reactions of diynes and dimethyl acetylenedicarboxylate, the rhodacyclopentadiene intermediate generated by oxidative coupling of a diyne and a monoyne with rhodium would also be involved